ROBO1 and neoplasm: Human primary NK cells have been tested in numerous clinical trials producing CAR-NK against specific tumor antigens, including ROBO1 for targeting several solid tumors (NCT03940820), PSMA for prostate cancer (NCT03692663), MSLN for epithelial ovarian cancer (NCT03692637) and Claudin6-for ovarian, testis cancer and refractory endometrial cancer (NCT05410717).